$-0.12 EPS Expected for CorMedix, Inc. (CRMD)

March 14, 2018 - By Lynda A. Deweese

 $ 0.12 EPS Expected for CorMedix, Inc. (CRMD)
Investors sentiment decreased to 0.67 in 2017 Q3. Its down 0.66, from 1.33 in 2017Q2. It dropped, as 4 investors sold CorMedix, Inc. shares while 8 reduced holdings. 4 funds opened positions while 4 raised stakes. 4.18 million shares or 60.52% less from 10.58 million shares in 2017Q2 were reported.
Sabby Management Ltd Liability reported 0.02% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD). State Street holds 17,767 shares or 0% of its portfolio. Bollard Grp Inc Ltd has 0.01% invested in CorMedix, Inc. (NYSEAMERICAN:CRMD). Bancorp Of America De reported 27,000 shares. Thompson Davis & Incorporated has invested 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD). Blackrock Inc stated it has 562,831 shares or 0% of all its holdings. Hightower Advsrs Llc has 67,188 shares. Wells Fargo And Com Mn invested 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD). Geode Cap Mngmt Ltd reported 0% stake. Morgan Stanley reported 4,211 shares stake. The Texas-based Ray Gerald L & Assocs Limited has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Taurus Asset Mngmt Ltd Liability reported 30,000 shares stake. Tci Wealth Advisors Incorporated reported 3,300 shares or 0% of all its holdings. The New York-based Bnp Paribas Arbitrage has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). 37,660 were reported by State Bank Of New York Mellon.

Analysts expect CorMedix, Inc. (NYSEAMERICAN:CRMD) to report $-0.12 EPS on March, 15.They anticipate $0.04 EPS change or 25.00 % from last quarter’s $-0.16 EPS. The stock decreased 3.31% or $0.0101 during the last trading session, reaching $0.295. About 1.02 million shares traded. CorMedix, Inc. (NYSEAMERICAN:CRMD) has declined 81.83% since March 14, 2017 and is downtrending. It has underperformed by 98.53% the S&P500.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. The company has market cap of $19.77 million. The Company’s primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. It currently has negative earnings. The firm was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.